Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Stephen G. Swisher"'
Autor:
Daniel R. Gomez, Jiangong Niu, David C. Rice, Jack A. Roth, Scott M. Atay, David B. Nelson, Ara A. Vaporciyan, Stephen G. Swisher, Mara B. Antonoff, Garrett L. Walsh, Anne Tsao, Wayne L. Hofstetter, Reza J. Mehran, Sharon H. Giordano, Boris Sepesi
Publikováno v:
Journal of Clinical Oncology. 35:3354-3362
Purpose Small observational studies have shown a survival advantage to undergoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if these results are generalizable. Our purpose was to evaluate survival after
Autor:
Apar Pataer, J. Jack Lee, Tina Cascone, Boris Sepesi, Anne S. Tsao, Wayne L. Hofstetter, Jianjun Zhang, Frank V. Fossella, William N. William, Don L. Gibbons, Stephen G. Swisher, Nicolas Zhou, Annikka Weissferdt, Myrna C.B. Godoy, Xiuning Le, Ara A. Vaporciyan, Cheuk Hong Leung, George R. Blumenschein, Heather Lin, John V. Heymach
Publikováno v:
Journal of Clinical Oncology. 39:8542-8542
8542 Background: The NEOSTAR study compared nivolumab (N) vs. nivolumab plus ipilimumab (NI) with major pathological response (MPR; ≤10% viable tumor) as primary outcome. We report updated rates of treatment failure (TF), including in patients whos
Autor:
Stephen G. Swisher, Linda Zhong, John V. Heymach, J. Jack Lee, Tito R. Mendoza, Ajay Sheshadri, Aung Naing, Abdulrazzak Zarifa, Jeff Lewis, Waree Rinsurongkawong, Fechukwu Akhmedzhanov, Mehmet Altan, Jianjun Zhang, Nathaniel R. Wilson, Vickie R. Shannon, Muhammad H. Arain, Felipe Soto
Publikováno v:
Journal of Clinical Oncology. 38:e15089-e15089
e15089 Background: Conventional treatments for advanced-stage non-small cell lung cancer (NSCLC) confer a progression-free survival of only about 6 months. Immune checkpoint inhibitors (ICIs) have become standard therapies in the management of advanc
Autor:
Mariela A. Blum, Manoop S. Bhutani, William A. Ross, Heath D. Skinner, Jaffer A. Ajani, Stephen G. Swisher, Ritsuko Komaki, Dipen M. Maru, Hironori Shiozaki, David C. Rice, Wayne L. Hofstetter, Kazuki Sudo, Lianchun Xiao, Takashi Taketa, Roopma Wadhwa, Jeffrey H. Lee, Elena Elimova, Brian Weston
Publikováno v:
Journal of Clinical Oncology. 32:3400-3405
Purpose Patients with esophageal carcinoma (EC) who are treated with definitive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses. In a large cohort, we assessed the timing, frequency, and types of relapses during an aggressiv
Autor:
Jing Wang, Ignacio I. Wistuba, Alexandre Reuben, Marcelo V. Negrao, Stephen G. Swisher, Hai T. Tran, Tatiana Karpinets, Ara A. Vaporciyan, Edwin Roger Parra Cuentas, Chantale Bernatchez, Lorenzo Federico, Cara Haymaker, Jianjun Zhang, John V. Heymach, Lixia Diao, Erin M. Corsini, Tina Cascone, Don L. Gibbons, Boris Sepesi, Kyle G. Mitchell
Publikováno v:
Journal of Clinical Oncology. 37:e14047-e14047
e14047 Background: Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with poor prognosis in non-small cell lung cancer (NSCLC); the biological underpinnings of this observation have not been fully elucidated. We examined the relations
Autor:
Brett W. Carter, George R. Blumenschein, Edwin Roger Parra Cuentas, Frank E. Mott, Tina Cascone, Frank V. Fossella, Heather Lin, Cheuk Hong Leung, Annikka Weissferdt, John V. Heymach, Boris Sepesi, Lorenzo Federico, Xiuning Le, Chantale Bernatchez, Stephen G. Swisher, Ara A. Vaporciyan, William N. William, Don L. Gibbons, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba
Publikováno v:
Journal of Clinical Oncology. 37:8504-8504
8504 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of NEOSTAR - a phase 2 trial of neoadjuvant N or NI for NSCLCs. Methods: Pts with sta
Autor:
Frank V. Fossella, George R. Simon, Anne S. Tsao, Heather Lin, Neda Kalhor, William N. William, John V. Heymach, Myrna C.B. Godoy, Frank E. Mott, Mara B. Antonoff, Boris Sepesi, Ara A. Vaporciyan, Charles Lu, Jianjun Zhang, Reza J. Mehran, Vincent K. Lam, Tina Cascone, J. Jack Lee, Stephen G. Swisher, David C. Rice
Publikováno v:
Journal of Clinical Oncology. 36:8555-8555
8555Background: Major pathologic response (mPR) in resected NSCLC following neoadjuvant chemotherapy correlates with long-term survival. This phase 1 study assessed the safety and efficacy of N add...
Autor:
J. Jack Lee, Xin Hu, John V. Heymach, Ignacio I. Wistuba, Junya Fujimoto, Humam Kadara, Andrew Futreal, Wenyong Sun, Runzhe Chen, Chi-Wan Chow, Xizeng Mao, Carmen Behrens, Jianhua Zhang, Jianjun Zhang, Chang-Jiun Wu, Paul Scheet, Stephen G. Swisher, Mara B. Antonoff, Xingzhi Song, Ara A. Vaporciyan
Publikováno v:
Journal of Clinical Oncology. 36:8576-8576
8576Background: Carcinogenesis may result from accumulation of genomic and epigenomic aberrations. It has been postulated that atypical adenomatous hyperplasia (AAH), the only recognized pre-neopla...
Autor:
Chang-Jiun Wu, Monique B. Nilsson, Stephen G. Swisher, Waree Rinsurongkawong, Xiuning Le, Bonnie S. Glisson, Andrew Futreal, John V. Heymach, Emily Roarty, Jianjun Zhang, Lara C.A. Landry, Marcelo V. Negrao, Alexandre Reuben, Jianhua Zhang, George R. Simon, Jacqulyne P. Robichaux
Publikováno v:
Journal of Clinical Oncology. 36:9052-9052
9052Background: Immune checkpoint blockade has led to unprecedented durable clinical benefit in metastatic non-small cell lung cancer (NSCLC), but response rates are low for patients with targetabl...
Autor:
Christopher I. Amos, Zhongxing Liao, Stephen G. Swisher, Jun Liu, Jian Gu, Arlene M. Correa, Silvia S. Chiang, Carol J. Etzel, Walter N. Hittelman, Xifeng Wu, L. Milas, Maosheng Huang, Jaffer A. Ajani, Tsung Teh Wu
Publikováno v:
Journal of Clinical Oncology. 24:3789-3798
PurposeUnderstanding how specific genetic variants modify drug action pathways may provide informative blueprints for individualized chemotherapy.MethodsWe applied a pathway-based approach to examine the impact of a comprehensive panel of genetic pol